Related Experiment Video
Updated: Aug 24, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.9K
Relationship Between Gut Bacteria and Levodopa Metabolism.
Kaifei Xu1, Shuo Sheng1, Feng Zhang1,2
1Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province and Laboratory Animal Center, Zunyi Medical University, Zunyi, Guizhou, China.
Current Neuropharmacology
|October 24, 2022
Summary
Gut bacteria metabolize levodopa, reducing its effectiveness for Parkinson's disease (PD). Strategies targeting intestinal bacteria can improve levodopa efficacy by minimizing this metabolism.
Area of Science:
- Neuroscience
- Microbiology
- Pharmacology
Background:
- Parkinson's disease (PD) involves the loss of dopamine neurons, with levodopa as the primary treatment.
- Levodopa's peripheral metabolism by gut microbiota reduces its bioavailability and therapeutic efficacy.
- Understanding levodopa's interaction with intestinal bacteria is crucial for optimizing PD treatment.
Approach:
- Reviewing current literature on levodopa metabolism by specific intestinal bacteria (e.g., Enterococcus faecalis, Eggerthella lenta, Clostridium sporogenes).
- Analyzing identified pathways that modulate levodopa metabolism within the gut microbiome.
- Evaluating strategies to inhibit bacterial levodopa metabolism and enhance drug effectiveness.
Key Points:
- Specific gut bacteria can significantly metabolize levodopa.
- Strategies like aromatic amino acid decarboxylase (AADC) inhibitors, antibiotics, pH modification, and (S)-α-fluoromethyltyrosine (AFMT) can reduce this metabolism.
- Minimizing peripheral levodopa breakdown is key to improving its delivery to the brain.
Conclusions:
- Intestinal bacteria play a significant role in levodopa's metabolic fate.
- Targeting gut microbiota metabolism offers a promising avenue for enhancing levodopa therapy in Parkinson's disease.
- Further research into these interactions can lead to improved treatment strategies for PD patients.
Related Concept Videos
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
532
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
532
01:24Parkinson's Disease: Treatment
353
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
353
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
679
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
679
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
374
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
374
01:21Drugs for Treatment of Constipation-Predominant IBS
293
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
293
01:29Bacterial Flora of the Large Intestine
575
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
575